经尿道水蒸气治疗(Rezūm)中每单位前列腺体积的治疗循环数(CPV)在依赖导尿管患者中的应用
这项前瞻性注册研究纳入168例依赖导尿管的患者,经倾向性评分匹配后分析144例,比较CPV≤0.15与CPV>0.15两组。结果显示CPV>0.15组1年IPSS更优(校正均差-2.8分,p=0.040),30天再入院率更低(4.2% vs 16.7%,OR 0.22,p=0.029)。结论提示对依赖导尿管患者,高于0.15的CPV可能优于基于视野的常规方法。
要点
- CPV>0.15组1年IPSS显著优于CPV≤0.15组(校正均差-2.8分,p=0.040)。
- CPV>0.15组30天再入院率显著更低(4.2% vs 16.7%,OR 0.22,p=0.029)。
- CPV>0.15组3个月PSA下降更明显(对数转换PSA校正均差-0.4 ng/ml,p=0.022)。
核心结论
- 在匹配队列中,Rezūm治疗时CPV>0.15与更优的1年IPSS和更低的30天再入院率相关。
- 与基于视野的标准方法相比,更积极的治疗策略可能使依赖导尿管患者获益。
研究设计与样本
- 前瞻性注册研究,2021年2月至2023年9月在三中心纳入168例连续依赖导尿管的Rezūm治疗患者。
- 按年龄和前列腺体积进行倾向性评分匹配后,144例患者以1:1比例分为CPV≤0.15组和CPV>0.15组进行分析。
- CPV计算为治疗循环数除以前列腺体积。
- 主要结局为1年随访时的IPSS;次要结局包括拔管时间、30天再入院率和PSA下降。
- 采用逻辑回归模型和线性混合模型进行统计分析。
主要发现
- CPV>0.15组1年IPSS显著更好(校正均差-2.8分,p=0.040)。
- CPV>0.15组30天再入院率显著更低(4.2% vs 16.7%,OR 0.22,p=0.029)。
- CPV>0.15组3个月PSA下降更明显(对数转换PSA校正均差-0.4 ng/ml,p=0.022)。
- 两组中位拔管时间分别为14天(四分位距9-29天)和15天(四分位距12-40天),p=0.059。
- 6周IPSS和IPSS-QoL两组相似(p分别为0.359和0.464)。
关键数值与推荐
- CPV分组阈值为0.15(CPV≤0.15 vs CPV>0.15)。
- 1年IPSS校正均差-2.8分(p=0.040)。
- 30天再入院率4.2% vs 16.7%(OR 0.22,p=0.029)。
- 3个月对数转换PSA校正均差-0.4 ng/ml(p=0.022)。
- 中位拔管时间14天(IQR 9-29) vs 15天(IQR 12-40),p=0.059。
临床怎么用
- 对依赖导尿管的难治性尿潴留患者,可考虑按前列腺体积计算治疗循环数(CPV>0.15),而非仅依据前列腺长度或视野。
- 提高CPV可能改善1年IPSS并降低30天再入院率,但需权衡更积极治疗的风险。
- 拔管时间、6周IPSS和IPSS-QoL在两组间无显著差异,决策时应结合个体情况。
局限性
- 研究为前瞻性注册研究,非随机对照,尽管进行了倾向性评分匹配,仍可能存在残余混杂。
- 样本量有限(匹配后144例),结论需更大样本验证。
- 随访时间主要为1年,长期疗效和安全性未报告。
- CPV阈值0.15为研究设定,尚未在外部人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For transurethral water vapor therapy (Rezūm), the number of water vapor treatment cycles has classically been determined by the prostate length, or the fields of vision (FOV). Apart from treating lower urinary tract symptoms, there is emerging evidence on Rezūm for refractory retention. We aim to investigate the optimal number of treatment cycles for Rezūm in catheter-dependent refractory retention. METHODS: From 02/2021 to 09/2023, 168 consecutive catheter-dependent patients undergoing Rezūm at three centres were included in this prospective registry. Treatment Cycles Per Unit Prostate Volume (CPV) was calculated by dividing the number of treatment cycles by the prostate size. After propensity score matching of age and prostate size, 144 patients were analyzed in the CPV ≤ 0.15 and CPV > 0.15 groups in 1:1 ratio. The primary outcome was the International Prostate Symptom Score (IPSS) at 1-year follow-up. Secondary outcomes included catheter removal time, 30-day readmission rates, prostate-specific antigen (PSA) reduction. Logistic regression model and linear mixed model were used. RESULTS: The CPV > 0.15 group demonstrated significantly better IPSS at 1-year follow-up (adjusted mean difference -2.8 points, p = 0.040), and lower 30-day readmission rates (4.2% vs 16.7%, OR 0.22, p = 0.029). Greater PSA reduction was observed in the higher CPV group at 3 months (adjusted mean difference of log-transformed PSA: -0.4 ng/ml, p = 0.022). Median catheter removal times were 14 days (interquartile range 9-29 days) and 15 days (interquartile range 12-40 days) for lower and higher CPV groups respectively (p = 0.059). Six-week IPSS and IPSS-QoL (quality of life score) were similar (p = 0.359 and p = 0.464 respectively). CONCLUSION: Higher CPV (>0.15) in Rezūm demonstrated superior 1-year IPSS, lower 30-day readmission rates in our matched cohort. A more aggressive treatment approach, contrasting to the standard FOV-based approach, may benefit catheter-dependent patients.
引用
- Siu BWH, Liu AQ, Leung CH, et al. Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients. Prostate Cancer Prostatic Dis. 2025. PMID: 40379864. doi:10.1038/s41391-025-00979-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。